Uncategorized – Page 435

MacroGenics and AbbVie Discontinue Development of ADAM9 Antibody-Drug Conjugate (IMGC936)

2 years ago talkbio0Tagged AbbVie, ADAM9 protein, human, Anti-ADAM9 ADC IMGC936, Effectiveness, issues, MacroGenics, Partnered ADC, Safety Concerns

MacroGenics, AbbVie, Partnered ADC, ADAM9, IMGC936, Early Data, Safety Concerns, Efficacy Issues

Brukinsa by BeiGene Secures FDA Approval for Follicular Lymphoma Amid Imbruvica Setbacks

2 years ago talkbio0Tagged Accelerated, Antibodies, Bispecific, Approved, BeiGene, Brukinsa, Chimeric Antigen Receptor T-cells, Clinical Trials, Combined Modality Therapy, competition, Disease Progression, Gazyva, Lymphoma, Follicular, obinutuzumab, ORR, Overall response rate, Rosewood, Toxicity aspects, United States Food and Drug Administration, zanubrutinib

Brukinsa (zanubrutinib), BeiGene, FDA approval, follicular lymphoma, accelerated approval, obinutuzumab (Gazyva) combination therapy, ROSEWOOD trial, overall response rate (ORR), disease progression or unacceptable toxicity, competition with CAR-T cell therapies/ bispecific antibodies

Biden Ramps Up Fight Against High Drug Prices in State of the Union Address

2 years ago talkbio0Tagged Addresses (publication format), Biden administration, Big Pharma, Commercial Drug Sales, drug price, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private insurance, Protections, Study models, Union

State of the Union Address, Biden Administration, Big Pharma, Drug Prices, Inflation Reduction Act, Medicare Drug Negotiations, Out-of-Pocket Cap Expansion, Private Insurance Protections, Generic Drug Cost-Sharing Limit, Cell & Gene Therapy Access Model, Commercial Drug Sales Rebates

FDA Greenlights Opdivo Combination Therapy for First-Line Bladder Cancer Treatment

2 years ago talkbio0Tagged cisplatin, Combined, Opdivo, Overall Survival

Overall Survival, Combined, cisplatin, Opdivo

BeiGene Scores Two Major FDA Approvals – Trivimbra for Esophageal Cancer and Brukinsa for Follicular Lymphoma

2 years ago talkbio0Tagged Accelerated Approval, Approved, BeiGene, Brukinsa, Esophageal Neoplasms, Lymphoma, Follicular, obinutuzumab, tislelizumab, Trivimbra, United States Food and Drug Administration, zanubrutinib

BeiGene, Trivimbra (tislelizumab), Esophageal Cancer, Brukinsa (zanubrutinib), Follicular Lymphoma, FDA Approval, Accelerated Approval, Obinutuzumab

Boehringer Ingelheim Caps Out-of-Pocket Costs for Asthma and COPD Inhalers in the U.S.

2 years ago talkbio0Tagged Asthma, boehringer ingelheim, Caps, Chronic Obstructive Airway Disease, Inhaler, June 1, 2024, List price reduction, Out of Pocket Payment, under-insured, Uninsured

Boehringer Ingelheim, Out-of-pocket costs, Asthma, COPD, Inhalers, $35 cap, June 1/ 2024, Uninsured and under-insured patients, List price reduction

Merck KGaA Abandons Evobrutinib Development, Emphasizes Deal-Focused Pipeline Strategy

2 years ago talkbio0Tagged BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, evobrutinib, Failed, Merck KGaA, Multiple Sclerosis, Phase 3 trials

Merck KGaA, Evobrutinib, BTK Inhibitor, Deal-driven Pipeline Strategy, Discontinuation of Development, Failed Phase 3 Trials, Multiple Sclerosis (MS) Treatment

Brukinsa Broadens Horizons: FDA Clears Follicular Lymphoma Combination Therapy

2 years ago talkbio0Tagged Accelerated, Approved, broadest label, Brukinsa, BTK Inhibitor, CHMP, Chronic lymphoma, Combined Modality Therapy, Lymphoma, Follicular, obinutuzumab, Oregon (geographic location), Overall response rate, Phase 2 Clinical Trials, Phase II ROSEWOOD trial, Recommendation, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Relapsing course, Rosewood, United States Food and Drug Administration

Brukinsa, Follicular lymphoma, FDA approval, BTK inhibitor, BTK inhibitor, Broadest label, Relapsed or refractory follicular lymphoma, ROSEWOOD Phase II study, CHMP positive opinion, Obinutuzumab combination therapy, Accelerated approval, Relapsed or refractory follicular lymphoma, Relapsed or refractory marginal zone lymphoma, Chronic lymphoma, CHMP recommendation, Phase II ROSEWOOD trial, Overall response rate (OR

Boundless Bio, Oncology Startup Targeting Extrachromosomal DNA, Files for $100 Million IPO

2 years ago talkbio0Tagged Arch of foot, Backed, Bayer, bleomycin/dacarbazine/lomustine/vincristine, Boundless, Checkpoint Kinase 1 Inhibitors, extrachromosomal DNA, IPO, Nasdaq Listing, Oncology Startup, Partner in relationship, Phase 1 Trials, Preliminary, Public Offering, Second Half of 2024, small molecule drugs, symbol

Boundless Bio, Oncology Startup, Initial Public Offering (IPO), Extrachromosomal DNA (ecDNA), Small Molecule Drugs (ecDTx), Checkpoint Kinase 1 Inhibitors, Phase 1 Trials, Nasdaq Listing (Symbol: BOLD), Backed by Bayer and Arch Venture Partners, Preliminary Data Expected in Second Half of 2024

Merck KGaA Abandons BTK Inhibitor Program, Emphasizes External Innovation

2 years ago talkbio0Tagged BTK Inhibitor, Clinical Trials, evobrutinib, External innovation strategy, Failed, Merck KGaA

Merck KGaA, BTK inhibitor, Evobrutinib, External innovation strategy, Failed clinical trials